Thrombosis in VEXAS syndrome

• DOI: 10.1007/s11239-021-02608-y
• Publication Date: 2021-11-24T16:03:50Z
• Authors: Thet Mon Oo; Jie Tian Jeanette...; Siew Fen Lee; Shang Ming Samuel...; Xin Rong Lim; Bingwen Eugene Fan
• Keywords: Male; 03 medical and health sciences; 0302 clinical medicine; Mutation; Humans; Thrombosis; Syndrome; Ubiquitin-Activating Enzymes; Venous Thromboembolism; Article; Aged; 3. Good health

VEXAS syndrome, an autoinflammatory syndrome due to a Ubiquitin Like Modifier Activating Enzyme 1 (UBA1) somatic mutation, has a high thrombotic burden. We report a case of a 69-year-old male that was diagnosed with VEXAS syndrome who developed venous thromboembolism (VTE). Review of literature of existing VEXAS syndrome cases showed a high thrombotic burden, with the reported incidence of VTE (36.4%) being markedly higher than arterial thrombosis (1.6%), with deep vein thrombosis being more common than pulmonary embolism. Somatic mutation in the UBA1 gene results in decreased ubiquitylation which is a key driver in the development of thrombosis in VEXAS syndrome, due to chronic inflammation and cytokine release from abnormal crosstalk between the intrinsic effector mechanism of innate immune cells, platelets and endothelium resulting in dysregulated haemostasis and endothelial dysfunction. Targeting endothelial dysfunction and reducing inflammatory milieu causing hypercoagulability with immunosuppressants and immunomodulatory agents, together with anticoagulation may be the strategy to prevent recurrent thrombotic events.